<?xml version="1.0" encoding="UTF-8"?>
<p>CHIKV-infected patients develop chikungunya fever (CHIKF), a febrile illness characterized with acute hallmark polyarthralgia, along with other disease manifestations like fever and maculopapular rash (
 <xref rid="B3" ref-type="bibr">3</xref>, 
 <xref rid="B16" ref-type="bibr">16</xref>, 
 <xref rid="B17" ref-type="bibr">17</xref>). Symptoms usually manifest after 4–7 days of incubation period (
 <xref rid="B3" ref-type="bibr">3</xref>). CHIKV infection has been shown by multiple studies to induce robust immune responses. Specifically, the type-I interferon (IFN)-associated pathways (
 <xref rid="B18" ref-type="bibr">18</xref>–
 <xref rid="B21" ref-type="bibr">21</xref>), the recruitment of innate and adaptive immune cells to the site of infection (
 <xref rid="B22" ref-type="bibr">22</xref>), and the development of protective antibodies for virus resolution (
 <xref rid="B23" ref-type="bibr">23</xref>–
 <xref rid="B29" ref-type="bibr">29</xref>), has been shown to contribute significantly to the self-limiting nature of CHIKF. Although CHIKV-induced symptoms usually resolve in patients within 2 weeks (
 <xref rid="B16" ref-type="bibr">16</xref>), ~30–40% of these patients go on to develop chronic arthritis, which can be due to inefficient viral clearance, or persistent immune response in patients (
 <xref rid="B3" ref-type="bibr">3</xref>, 
 <xref rid="B16" ref-type="bibr">16</xref>, 
 <xref rid="B18" ref-type="bibr">18</xref>).
</p>
